RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...
Stocktwits on MSN23h
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock DropsShares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback